Empagliflozin and Incidence of Events Consistent With Acute Kidney Injury: Pooled Safety Analysis in >15,000 Individuals
Diabetes Obes Metab 2022;doi:10.1111/dom.14694 Ahead of print
Agarwal et al. analysed pooled safety datasets in the global empagliflozin trial programme to investigate the incidence of investigator-reported acute kidney events with focus on patient groups at risk of acute kidney events during the first 30 days after treatment initiation.
